Bicycle Therapeutics Plc (NASDAQ: BCYC)
Bicycle Therapeutics Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Bicycle Therapeutics Plc Company Info
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
News & Analysis
Bicycle (BCYC) Q2 Revenue Falls 69%
Why Shares of Bicycle Therapeutics Were Rising on Monday
The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy.
Why Bicycle Therapeutics Stock Raced Ahead Today
The company's latest attempt at capital raising seems to be having enviable success.
Here's Why Bicycle Therapeutics Stock Looks Ill Today
Lackluster clinical trial results for its lead candidate are to blame.
Is Bicycle Therapeutics Stock a Buy?
This biotech company was founded by a Nobel laureate.
3 Ultra-Risky Biotech Stocks That Could Make You Filthy Rich
Clinical trial successes could send shares of these drugmakers screaming higher.
5 Absurdly Cheap Biotech Stocks That Could Make You Filthy Rich
These five biotech stocks could post life-changing gains for early-bird investors.
2 High-Growth Stocks I’m Buying Right Now
These two clinical-stage biotechs could yield exponential returns for early investors.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.